Clinical Sciences, Epidemiology, and Research, Fresenius Medical Care, North America, Waltham, Massachusetts 02451-1457, USA.
Clin J Am Soc Nephrol. 2010 Feb;5(2):252-60. doi: 10.2215/CJN.07231009. Epub 2009 Dec 17.
The Short Form 12 (SF-12) has not been validated for long-term dialysis patients. The study compared physical and mental component summary (PCS/MCS) scores from the SF-36 with those from the embedded SF-12 in a national cohort of dialysis patients.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: All 44,395 patients who had scorable SF-36 and SF-12 from January 1, 2006, to December 31, 2006, and were treated at Fresenius Medical Care, North America facilities were included. Death and first hospitalization were followed for up to 1 year from the date of survey. Correlation and agreement were obtained between PCS-36 and PCS-12 and MCS-36 and MCS-12; then Cox models were constructed to compare associated hazard ratios (HRs) between them.
Physical and mental dimensions both exhibited excellent intraclass correlation coefficients of 0.94. Each incremental point for both PCS-12 and PCS-36 was associated with a 2.4% lower adjusted HR of death and 0.4% decline in HR for first hospitalization (both P < 0.0001). Corresponding improvement in HR of death for each MCS point was 1.2% for MCS-12 and 1.3% for MCS-36, whereas both had similar 0.6% lower HR for hospitalization per point (all P < 0.0001).
The use of the SF-12 alone or as part of a larger survey is valid in dialysis patients. Composite scores from the SF-12 and SF-36 have similar prognostic association with death and hospitalization risk. Prospective longitudinal studies of SF-12 surveys that consider responsiveness to specific clinical, situational, and interventional changes are needed in this population.
SF-12 量表尚未在长期透析患者中得到验证。本研究比较了全国性透析患者队列中 SF-36 的生理和心理成分综合评分(PCS/MCS)与嵌入 SF-12 的 PCS/MCS 评分。
设计、设置、参与者和测量:纳入 2006 年 1 月 1 日至 12 月 31 日期间在 Fresenius Medical Care,North America 接受治疗且 SF-36 和 SF-12 评分可评估的所有 44395 例患者。从调查日期起,对死亡和首次住院进行了长达 1 年的随访。获得了 PCS-36 和 PCS-12 以及 MCS-36 和 MCS-12 之间的相关性和一致性;然后构建了 Cox 模型以比较它们之间相关的危险比(HR)。
生理和心理维度均表现出优异的组内相关系数 0.94。PCS-12 和 PCS-36 的每增加 1 分,死亡的调整后 HR 降低 2.4%,首次住院的 HR 降低 0.4%(均 P<0.0001)。对于 MCS 点,每增加一个点,死亡的 HR 相应改善 1.2%(MCS-12)和 1.3%(MCS-36),而每增加一个点,住院的 HR 均降低 0.6%(均 P<0.0001)。
SF-12 单独使用或作为更大规模调查的一部分在透析患者中是有效的。SF-12 和 SF-36 的综合评分与死亡和住院风险具有相似的预后相关性。在该人群中需要进行前瞻性纵向研究,以评估 SF-12 调查对特定临床、情境和干预变化的反应能力。